Terms: = Leukemia AND RUNX1T1, ENSG00000079102, 862 AND Treatment
95 results:
1. Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19 Pandemic: A Cluster Randomized Clinical Trial.
Meredith LS; Ahluwalia S; Chen PG; Dong L; Farmer CM; Bouskill KE; Dalton S; Qureshi N; Blagg T; Timmins G; Schulson LB; Huilgol SS; Han B; Williamson S; Watson P; Schnurr PP; Martineau M; Davis K; Cassells A; Tobin JN; Gidengil C
JAMA Netw Open; 2024 Apr; 7(4):e244192. PubMed ID: 38687482
[TBL] [Abstract] [Full Text] [Related]
2. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
[TBL] [Abstract] [Full Text] [Related]
3. Mixed-phenotype acute leukemia, T/megakaryoblastic: does it really exist?
Mansoor N; Javed O; Rafiq N; Aali A; Meraj F
J Hematop; 2023 Mar; 16(1):49-55. PubMed ID: 38175376
[TBL] [Abstract] [Full Text] [Related]
4. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract] [Full Text] [Related]
5. Automated Deep Learning-Based Diagnosis and Molecular Characterization of Acute Myeloid leukemia Using Flow Cytometry.
Lewis JE; Cooper LAD; Jaye DL; Pozdnyakova O
Mod Pathol; 2024 Jan; 37(1):100373. PubMed ID: 37925056
[TBL] [Abstract] [Full Text] [Related]
6. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients.
Zong L; Yin M; Kong J; Zhang J; Song B; Zhu J; Xue S; Wu X; Wu D; Bao X; Qiu H
Mol Carcinog; 2023 Oct; 62(10):1572-1584. PubMed ID: 37555764
[TBL] [Abstract] [Full Text] [Related]
7. Systemic Mastocytosis with Associated Hematological Neoplasms. Diagnostic features and unique response pattern to tyrosine kinase inhibitors and allo-bone marrow transplantation therapy.
Hernández Alconchel I; González de Villambrosía S; Insunza Gaminde A; Montes Moreno S
Rev Esp Patol; 2023; 56(3):180-185. PubMed ID: 37419556
[TBL] [Abstract] [Full Text] [Related]
8. CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Shen YJ; Zhang Y; Chang J; Wang HF; Ye XN; Zhu L; Jin J; Zhu HH
Ann Hematol; 2023 Jul; 102(7):1731-1738. PubMed ID: 37145324
[TBL] [Abstract] [Full Text] [Related]
9. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.
Kong J; Zheng FM; Wang ZD; Zhang YY; Cheng YF; Fu HX; Lv M; Chen H; Xu LP; Zhang XH; Huang XJ; Wang Y
Bone Marrow Transplant; 2023 Jul; 58(7):777-783. PubMed ID: 37024571
[TBL] [Abstract] [Full Text] [Related]
10. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
[TBL] [Abstract] [Full Text] [Related]
11. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study.
Scott S; Dillon R; Thiede C; Sadiq S; Cartwright A; Clouston HJ; Travis D; Mokretar K; Potter N; Chantry A; Whitby L
Blood Adv; 2023 Jul; 7(14):3686-3694. PubMed ID: 36939402
[TBL] [Abstract] [Full Text] [Related]
12. Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid leukemia.
Gudipati M; Butler M; Koka R; Baer MR; Ning Y
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833323
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive molecular understanding of pediatric acute myeloid leukemia.
Shiba N
Int J Hematol; 2023 Feb; 117(2):173-181. PubMed ID: 36653696
[TBL] [Abstract] [Full Text] [Related]
14. Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia.
Karlsson L; Nyvold CG; Soboli A; Johansson P; Palmqvist L; Tierens A; Hasle H; Lausen B; Jónsson ÓG; Jürgensen GW; Ebbesen LH; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2022 Dec; 44(6):1094-1101. PubMed ID: 35918824
[TBL] [Abstract] [Full Text] [Related]
15. Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literature.
Akhila Raj TV; Gopinath P; Geetha Raj JA; Narayanan G; Nair SG; Joy Philip DS; Raveendran S; Geetha P; Sreedharan H
J Cancer Res Ther; 2022; 18(3):697-703. PubMed ID: 35900542
[TBL] [Abstract] [Full Text] [Related]
16. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid leukemia.
Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
[TBL] [Abstract] [Full Text] [Related]
17. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
18. Case Report: Preemptive treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid leukemia With RUNX1-runx1t1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract] [Full Text] [Related]
19. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract] [Full Text] [Related]
20. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract] [Full Text] [Related]
[Next]
